NASDAQ:BOLT
Bolt Biotherapeutics
- Stock
0.35
−1.21%
−5.18
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus